As Dr Wang explains, the combination of robust efficacy, manageable toxicity, and longer follow-up—along with pooled data ...
In the discussion, Richard Goldberg, MD, a gastrointestinal oncologist at the WVU Cancer Institute, highlighted a fundamental ...
ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.
In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
Dr Singh also takes viewers inside the critical—and often underappreciated—role of multidisciplinary collaboration, ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results